

GUIDED THERAPEUTICS INC  
Form 8-K  
November 15, 2012

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event) November 15, 2012; (November 13, 2012)

**GUIDED THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware                                      0-22179                                      58-2029543  
(State or Other Jurisdiction of   (Commission File Number) (IRS Employer Identification No.)

Incorporation)

**5835 Peachtree Corners East, Suite D**

**30092**

**Norcross, Georgia**

(Zip Code)

(Address of Principal Executive Offices)

Registrant's Telephone Number, Including Area Code: **(770) 242-8723**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Section 2.02 Results of Operations and Financial Condition

On November 13, 2012, the registrant publicly released its financial results for the third quarter ended September 30, 2012, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

## Section 7.01 (Regulation FD Disclosure)

On November 13, 2012, the registrant publicly issued a press release announcing it had submitted an amendment to its premarket application submission with the U.S. Food and Drug Administration for the Company's LuViv<sup>®</sup> Advanced Cervical Scan, currently under review by the agency, as more fully described in the press release, a copy of which is furnished as Exhibit 99.3 hereto and which information is incorporated herein by reference.

On November 14, 2012, the registrant conducted a conference call discussing its financial results for the third quarter ended September 30, 2012 and other matters concerning the operation of the company, as more fully described in the prepared transcript of the call, a copy of which is furnished as Exhibit 99.2 hereto and which information is incorporated herein by reference.

## Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits.*

### Number Exhibit

99.1 Press Release dated November 13, 2012

99.2 Call transcript

99.3 Press Release dated November 13, 2012

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GUIDED THERAPEUTICS, INC.**

By: /s/ Mark L. Faupel, Ph.D.

Edgar Filing: GUIDED THERAPEUTICS INC - Form 8-K

Mark L. Faupel, Ph.D.  
CEO & President

Date: November 15, 2012

